368 related articles for article (PubMed ID: 33740526)
21. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
[TBL] [Abstract][Full Text] [Related]
22. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.
Sam S; Ehrmann DA
Diabetologia; 2017 Sep; 60(9):1656-1661. PubMed ID: 28770330
[TBL] [Abstract][Full Text] [Related]
23. Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome.
Wang Z; Nie K; Su H; Tang Y; Wang H; Xu X; Dong H
Phytomedicine; 2021 Oct; 91():153654. PubMed ID: 34333328
[TBL] [Abstract][Full Text] [Related]
24. Berberine Improves the Symptoms of DHEA-Induced PCOS Rats by Regulating Gut Microbiotas and Metabolites.
Shen HR; Xu X; Ye D; Li XL
Gynecol Obstet Invest; 2021; 86(4):388-397. PubMed ID: 34515131
[TBL] [Abstract][Full Text] [Related]
25. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y
Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
[TBL] [Abstract][Full Text] [Related]
26. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
[TBL] [Abstract][Full Text] [Related]
27. Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome.
Zhu TW; Li XL
Clin Exp Pharmacol Physiol; 2023 Nov; 50(11):835-843. PubMed ID: 37604463
[TBL] [Abstract][Full Text] [Related]
28. Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance.
Herman R; Sikonja J; Jensterle M; Janez A; Dolzan V
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834549
[TBL] [Abstract][Full Text] [Related]
29. The effect of cinnamon on polycystic ovary syndrome in a mouse model.
Dou L; Zheng Y; Li L; Gui X; Chen Y; Yu M; Guo Y
Reprod Biol Endocrinol; 2018 Oct; 16(1):99. PubMed ID: 30340496
[TBL] [Abstract][Full Text] [Related]
30. Potential Role of Quercetin in Polycystic Ovary Syndrome and Its Complications: A Review.
Chen T; Jia F; Yu Y; Zhang W; Wang C; Zhu S; Zhang N; Liu X
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889348
[TBL] [Abstract][Full Text] [Related]
31. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Zeng X; Xie YJ; Liu YT; Long SL; Mo ZC
Clin Chim Acta; 2020 Mar; 502():214-221. PubMed ID: 31733195
[TBL] [Abstract][Full Text] [Related]
32. Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways.
Zhang N; Liu X; Zhuang L; Liu X; Zhao H; Shan Y; Liu Z; Li F; Wang Y; Fang J
Regul Toxicol Pharmacol; 2020 Feb; 110():104544. PubMed ID: 31778716
[TBL] [Abstract][Full Text] [Related]
33. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects.
Ruan X; Kubba A; Aguilar A; Mueck AO
Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):183-190. PubMed ID: 28463030
[TBL] [Abstract][Full Text] [Related]
34. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome.
Barrea L; Marzullo P; Muscogiuri G; Di Somma C; Scacchi M; Orio F; Aimaretti G; Colao A; Savastano S
Nutr Res Rev; 2018 Dec; 31(2):291-301. PubMed ID: 30033891
[TBL] [Abstract][Full Text] [Related]
35. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction.
González F
Semin Reprod Med; 2015 Jul; 33(4):276-86. PubMed ID: 26132932
[TBL] [Abstract][Full Text] [Related]
36. [Application of metabolomics in treating polycystic ovary syndrome with berberine based on ultra high performance liquid chromatography-mass spectrometry].
Li Y; Zhang C; Zhang H; Zhao X; Hou L; Xu G
Se Pu; 2014 May; 32(5):464-71. PubMed ID: 25185305
[TBL] [Abstract][Full Text] [Related]
37. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS).
Li Y; Chen C; Ma Y; Xiao J; Luo G; Li Y; Wu D
Life Sci; 2019 Jul; 228():167-175. PubMed ID: 31029778
[TBL] [Abstract][Full Text] [Related]
38. Polycystic ovary syndrome management: a review of the possible amazing role of berberine.
Rondanelli M; Infantino V; Riva A; Petrangolini G; Faliva MA; Peroni G; Naso M; Nichetti M; Spadaccini D; Gasparri C; Perna S
Arch Gynecol Obstet; 2020 Jan; 301(1):53-60. PubMed ID: 32060683
[TBL] [Abstract][Full Text] [Related]
39. Metformin and sitagliptin combination therapy ameliorates polycystic ovary syndrome with insulin resistance through upregulation of lncRNA H19.
Wang Q; Shang J; Zhang Y; Zhou W
Cell Cycle; 2019 Oct; 18(19):2538-2549. PubMed ID: 31405334
[TBL] [Abstract][Full Text] [Related]
40. Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome.
Wang Y; Fu X; Xu J; Wang Q; Kuang H
Sci Rep; 2016 Jun; 6():28089. PubMed ID: 27306862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
